Sign In
Buy XENE
$53.46
+1.16 (+2.22%)
At Close: Jun 03, 2026
Xenon Pharmaceuticals Announces Collaboration with Neurocrine Biosciences Achieves $15.0 Million Regulatory Milestone
01:00pm, Wednesday, 12'th Jan 2022 GlobeNewswire Inc.
BURNABY, British Columbia, Jan. 12, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develo
Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2022
01:30pm, Monday, 10'th Jan 2022 GlobeNewswire Inc.
BURNABY, British Columbia, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today outlined its key milestones for 2022.
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
07:30pm, Wednesday, 29'th Dec 2021 Benzinga
For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chico said Wednesday on "PreMarket Prep Plus."
Chico, the senior
Wednesdays With Wedbush: Analyst Laura Chico On The State Of Biotech
02:30pm, Wednesday, 29'th Dec 2021
For most issues in the biotech sector, it was a rough 2021, especially when compared to the gains in the S&P 500 index, Wedbush's Laura Chico said Wednesday on "PreMarket Prep Plus." Chico, the senior
Brokerages Anticipate Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Will Post Earnings of -$0.42 Per Share
04:06pm, Sunday, 12'th Dec 2021 Transcript Daily
Brokerages expect Xenon Pharmaceuticals Inc. (NASDAQ:XENE) to announce earnings of ($0.42) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have issued estimates for Xenon Pharmaceuticals earnings, with the highest EPS estimate coming in at ($0.29) and the lowest estimate coming in at ($0.67). Xenon Pharmaceuticals reported earnings of ($0.34) per []
Xenon Pharmaceuticals jumps 5% on insider buying worth $100K
07:48pm, Wednesday, 08'th Dec 2021 Seeking Alpha
Xenon Pharmaceuticals (XENE) Investor Presentation - Slideshow
05:38pm, Monday, 06'th Dec 2021 Seeking Alpha
The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering
12:40pm, Friday, 03'rd Dec 2021 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Protagonist to Discontinue Development Of Early-Stage Inflammatory Diseases Drug And Focus On PN-235
P
Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)
12:00pm, Friday, 03'rd Dec 2021 GlobeNewswire Inc.
Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups
Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b X-TOLE Clinical Trial at the Annual Meeting of the American Epilepsy Society (AES 2021)
12:00pm, Friday, 03'rd Dec 2021 Intrado Digital Media
Topline Data Showed All Primary and Secondary Seizure Reduction Endpoints Statistically Significant Across All Dose Groups, with p-value of <0.001 for 20 mg and 25 mg Dose Groups
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2021)
11:55am, Friday, 03'rd Dec 2021 GlobeNewswire Inc.
BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on
Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2021)
11:55am, Friday, 03'rd Dec 2021 Intrado Digital Media
BURNABY, British Columbia, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that it will provide updates on its proprietary, neurology programs at the Annual Meeting of the American Epilepsy Society (AES 2021).
Xenon Stock Jumps On New Encouraging Data From Epilepsy Treatment
09:00am, Friday, 03'rd Dec 2021
Xenon Pharmaceuticals Inc (NASDAQ: XENE) announced additional positive data from new sub-analyses of Phase 2b X-TOLE trial of XEN1101 in adult patients with focal epilepsy. The Data will be present
The Week Ahead In Biotech (Nov. 28-Dec. 4): FDA Decisions For VBI Vaccines, BeyondSpring, CTI Biopharma And Merck Take The Spotlight In A Light Calendar Week
02:43pm, Sunday, 28'th Nov 2021 Benzinga
Biotech stocks advanced in the week ending Nov. 26, as a late-week surge on the back of news about a new COVID-19 variant, named Omicron, helped mitigate the losses notched earlier in the holiday-s
